Decanethiol Functionalized Silver Nanoparticles Are New Powerful Leishmanicidals in Vitro

Overview

Journal World J Microbiol Biotechnol

Publisher Springer

Specialties Biotechnology
Microbiology

Date 2018 Feb 21

PMID 29460068

Citations 4

Authors

A P Isaac-Marquez

P Talamas-Rohana

N Galindo-Sevilla

S E Gaitan-Puch

N A Diaz-Diaz

G A Hernandez-Ballina

C M Lezama-Davila

Affiliations

Soon will be listed here.

Abstract

We evaluated, for the first time, the leishmanicidal potential of decanethiol functionalized silver nanoparticles (AgNps-SCH) on promastigotes and amastigotes of different strains and species of Leishmania: L. mexicana and L. major isolated from different patients suffering from localized cutaneous leishmaniasis (CL) and L. mexicana isolated from a patient suffering from diffuse cutaneous leishmaniasis (DCL). We recorded the kinetics of promastigote growth by daily parasite counting for 5 days, promastigote mobility, parasite reproduction by CFSE staining's protocol and promastigote killing using the propidium iodide assay. We also recorded IC's of promastigotes and amastigotes, therapeutic index, and cytotoxicity by co-culturing macrophages with AgNps-SCH or sodium stibogluconate (Sb) used as reference drug. We used Sb as a reference drug since it is used as the first line treatment for all different types of leishmaniasis. At concentrations 10,000 times lower than those used with Sb, AgNps-SCH had a remarkable leishmanicidal effect in all tested strains of parasites and there was no toxicity to J774A.1 macrophages since > 85% were viable at the concentrations used. Therapeutic index was about 20,000 fold greater than the corresponding one for Sb treated cells. AgNps-SCH inhibited > 80% promastigote proliferation in all tested parasites. These results demonstrate there is a high leishmanicidal potential of AgNps-SCH at concentrations of 0.04 µM. Although more studies are needed, including in vivo testing of AgNps-SCH against different types of leishmaniasis, they can be considered a potential new treatment alternative.

Citing Articles

In vitro leishmanicidal activity of two cholesterol derivatives.

Isaac-Marquez A, Lezama-Davila C World J Microbiol Biotechnol. 2022; 38(4):66.

PMID: 35246768 DOI: 10.1007/s11274-022-03248-x.

Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles.

Want M, Yadav P, Khan R, Chouhan G, Islamuddin M, Aloyouni S Int J Nanomedicine. 2021; 16:7285-7295.

PMID: 34737566 PMC: 8560327. DOI: 10.2147/IJN.S268548.

Biogenic Silver Nanoparticles Can Control Infection in Both Human Trophoblast Cells and Villous Explants.

Nazareth Costa I, Ribeiro M, Franco P, da Silva R, de Araujo T, Milian I Front Microbiol. 2021; 11:623947.

PMID: 33552033 PMC: 7858645. DOI: 10.3389/fmicb.2020.623947.

Development of an automated image analysis protocol for quantification of intracellular forms of Leishmania spp.

Gomes-Alves A, Maia A, Cruz T, Castro H, Tomas A PLoS One. 2018; 13(8):e0201747.

PMID: 30071097 PMC: 6072083. DOI: 10.1371/journal.pone.0201747.

References

Allahverdiyev A, Abamor E, Bagirova M, Baydar S, Canim Ates S, Kaya F . Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro. Exp Parasitol. 2013; 135(1):55-63. DOI: 10.1016/j.exppara.2013.06.001. View

Messaritakis I, Mazeris A, Koutala E, Antoniou M . Leishmania donovani s.l.: evaluation of the proliferation potential of promastigotes using CFSE staining and flow cytometry. Exp Parasitol. 2010; 125(4):384-8. DOI: 10.1016/j.exppara.2010.03.006. View

Oryan A, Akbari M . Worldwide risk factors in leishmaniasis. Asian Pac J Trop Med. 2016; 9(10):925-932. DOI: 10.1016/j.apjtm.2016.06.021. View

Isaac-Marquez A, McChesney J, Nanayakara N, Satoskar A, Lezama-Davila C . Leishmanicidal activity of racemic +/- 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline. Nat Prod Commun. 2010; 5(3):387-90. View

Nilforoushzadeh M, Shirani-Bidabadi L, Zolfaghari-Baghbaderani A, Jafari R, Heidari-Beni M, Siadat A . Topical effectiveness of different concentrations of nanosilver solution on Leishmania major lesions in Balb/c mice. J Vector Borne Dis. 2013; 49(4):249-53. View

Foglieni C, Meoni C, Davalli A . Fluorescent dyes for cell viability: an application on prefixed conditions. Histochem Cell Biol. 2001; 115(3):223-9. DOI: 10.1007/s004180100249. View

Gonzalez-Carter D, Leo B, Ruenraroengsak P, Chen S, Goode A, Theodorou I . Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of HS-synthesizing enzymes. Sci Rep. 2017; 7:42871. PMC: 5333087. DOI: 10.1038/srep42871. View

Dai X, Guo Q, Zhao Y, Zhang P, Zhang T, Zhang X . Functional Silver Nanoparticle as a Benign Antimicrobial Agent That Eradicates Antibiotic-Resistant Bacteria and Promotes Wound Healing. ACS Appl Mater Interfaces. 2016; 8(39):25798-25807. DOI: 10.1021/acsami.6b09267. View

Gutierrez V, Seabra A, Reguera R, Khandare J, Calderon M . New approaches from nanomedicine for treating leishmaniasis. Chem Soc Rev. 2015; 45(1):152-68. DOI: 10.1039/c5cs00674k. View

10.

Ahmad A, Wei Y, Syed F, Khan S, Khan G, Tahir K . Isatis tinctoria mediated synthesis of amphotericin B-bound silver nanoparticles with enhanced photoinduced antileishmanial activity: A novel green approach. J Photochem Photobiol B. 2016; 161:17-24. DOI: 10.1016/j.jphotobiol.2016.05.003. View

11.

Allahverdiyev A, Abamor E, Bagirova M, Ustundag C, Kaya C, Kaya F . Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. Int J Nanomedicine. 2011; 6:2705-14. PMC: 3218584. DOI: 10.2147/IJN.S23883. View

12.

Zhang X, Liu Z, Shen W, Gurunathan S . Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int J Mol Sci. 2016; 17(9). PMC: 5037809. DOI: 10.3390/ijms17091534. View

13.

Mlika B, Aidli S, Ben Brahim M, Badri T, Chouk S, Ben Jannet S . [Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia]. Med Trop (Mars). 2008; 68(5):499-501. View

14.

Natera S, Machuca C, Padron-Nieves M, Romero A, Diaz E, Ponte-Sucre A . Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents. 2007; 29(6):637-42. DOI: 10.1016/j.ijantimicag.2007.01.004. View

15.

Arvizo R, Miranda O, Thompson M, Pabelick C, Bhattacharya R, Robertson J . Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010; 10(7):2543-8. PMC: 2925219. DOI: 10.1021/nl101140t. View

16.

Kalangi S, Dayakar A, Gangappa D, Sathyavathi R, Maurya R, Rao D . Biocompatible silver nanoparticles reduced from Anethum graveolens leaf extract augments the antileishmanial efficacy of miltefosine. Exp Parasitol. 2016; 170:184-192. DOI: 10.1016/j.exppara.2016.09.002. View

17.

Lezama-Davila C, Isaac-Marquez A, Kapadia G, Owens K, Oghumu S, Beverley S . Leishmanicidal activity of two naphthoquinones against Leishmania donovani. Biol Pharm Bull. 2012; 35(10):1761-4. PMC: 3693454. DOI: 10.1248/bpb.b12-00419. View

18.

Abamor E, Allahverdiyev A . A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations. Exp Parasitol. 2016; 166:150-63. DOI: 10.1016/j.exppara.2016.04.008. View

19.

Kumar R, Engwerda C . Vaccines to prevent leishmaniasis. Clin Transl Immunology. 2014; 3(3):e13. PMC: 4232054. DOI: 10.1038/cti.2014.4. View

20.

Lezama-Davila C, Pan L, Isaac-Marquez A, Terrazas C, Oghumu S, Isaac-Marquez R . Pentalinon andrieuxii root extract is effective in the topical treatment of cutaneous leishmaniasis caused by Leishmania mexicana. Phytother Res. 2013; 28(6):909-16. PMC: 4136428. DOI: 10.1002/ptr.5079. View